CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Hu, YX; Zhou, YL; Zhang, MM; Ge, WG; Li, Y; Yang, L; Wei, GQ; Han, L; Wang, H; Yu, SH; Chen, Y; Wang, YB; He, XH; Zhang, XW; Gao, M; Yang, JJ; Li, XJ; Ren, JT; Huang, H

Ren, JT; Huang, H (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, 79 Qingchun Rd, Hangzhou 310003, Peoples R China.

CLINICAL CANCER RESEARCH, 2021; 27 (10): 2764

Abstract

Purpose: Autologous chimeric antigen receptor T (CAR-T) cell therapy is an effective treatment for relapsed/refractory acute lymphoblastic leukemia (r......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索